Novel agonists and antagonists for human protease activated receptor 2.
about
Characterization and Functions of Protease-Activated Receptor 2 in Obesity, Diabetes, and Metabolic Syndrome: A Systematic ReviewDevelopment and evaluation of small peptidomimetic ligands to protease-activated receptor-2 (PAR2) through the use of lipid tetheringThe Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptorsPAR2 Modulators Derived from GB88.Pathway-selective antagonism of proteinase activated receptor 2.Attenuated vasodilator effectiveness of protease-activated receptor 2 agonist in heterozygous par2 knockout mice.Protease-activated receptors in the Achilles tendon-a potential explanation for the excessive pain signalling in tendinopathyModulating human proteinase activated receptor 2 with a novel antagonist (GB88) and agonist (GB110).The novel PAR2 ligand C391 blocks multiple PAR2 signalling pathways in vitro and in vivo.Pharmacophore-based virtual screening, biological evaluation and binding mode analysis of a novel protease-activated receptor 2 antagonist.Development of highly potent protease-activated receptor 2 agonists via synthetic lipid tethering.Teleocidin A2 inhibits human proteinase-activated receptor 2 signaling in tumor cells.Recent progress in tight junction modulation for improving bioavailability.Neutrophil elastase induces inflammation and pain in mouse knee joints via activation of proteinase-activated receptor-2.Indanes--Properties, Preparation, and Presence in Ligands for G Protein Coupled Receptors.Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Proteinases, Their Extracellular Targets, and Inflammatory Signaling.Factor VIIa regulates the expression of caspase-3, MMP-9, and CD44 in SW620 colon cancer cells involving PAR2/MAPKs/NF-κB signaling pathways.Immunomodulatory role of proteinase-activated receptor-2Protease-Activated Receptor 2 Promotes Pro-Atherogenic Effects through Transactivation of the VEGF Receptor 2 in Human Vascular Smooth Muscle Cells.Antagonism of the proinflammatory and pronociceptive actions of canonical and biased agonists of protease-activated receptor-2.Factor Xa Mediates Calcium Flux in Endothelial Cells and is Potentiated by Igg From Patients With Lupus and/or Antiphospholipid Syndrome.Potent Small Agonists of Protease Activated Receptor 2.PAR2-induced inflammatory responses in human kidney tubular epithelial cells.Protease activated receptor 2 controls myelin development, resiliency and repair.Tryptase potentiates enteric nerve activation by histamine and serotonin: Relevance for the effects of mucosal biopsy supernatants from irritable bowel syndrome patients.Effects of chronic in-vivo treatments with protease-activated receptor 2 agonist on endothelium function and blood pressures in mice.Characterization of Protease-Activated Receptor (PAR) ligands: Parmodulins are reversible allosteric inhibitors of PAR1-driven calcium mobilization in endothelial cells.Protease activated receptor-2 (PAR2): possible target of phytochemicals.Chitinase-3-like protein 1 protects skeletal muscle from TNFα-induced inflammation and insulin resistance.Signaling Crosstalk of TGF-β/ALK5 and PAR2/PAR1: A Complex Regulatory Network Controlling Fibrosis and Cancer.
P2860
Q26752383-B6E7056E-4239-4258-94A9-110919866D00Q28539692-E666FE51-03A1-4C8C-9739-FA6D630737C5Q30486707-F41CF980-E4B7-462F-B53B-B8110AED5151Q34547663-0B56542F-0A30-46C1-9E69-922EEA930CDCQ34571419-D4D429F2-26CC-4829-9F4F-ED608113EBF9Q34586508-B779EDB6-D0EF-42F3-983E-11CDCE98DA31Q35204291-46C88F79-4082-45F6-9514-95859AD1E3B0Q36024903-EB1388CC-53F0-4FEE-BD31-66E8923F3062Q36036250-94041709-BB1A-471F-B363-D541CCD59C87Q36124531-BD14BF81-81BD-4E3C-A8C2-83A53F0B21FDQ36710897-BA504EE3-8964-4512-A02C-DEA178CE5089Q37591794-F557E9D6-56C7-487C-9204-D4A055DA55A1Q38190079-97C77076-EAF0-4244-885E-7D03F1574E46Q38263507-9429AAF8-71A8-4929-B819-1CE254B70E47Q38505134-FA1416D9-F4EF-4AA9-8E4E-BFF949B9FFB2Q38758445-52DE7B9E-2454-439F-BCD7-F0B21BA322FAQ38966192-EEFCE2F3-5010-4734-88DA-1484F3ADFAB8Q39241236-79D20837-F78B-4DF6-BCF7-A416195DDEE0Q39620746-080BDA40-0841-4900-ACE0-C0E282EC9377Q40630385-4EE345C5-087F-4007-967C-AAE05D3FA1BBQ41341638-FFA27E02-F115-456F-9381-267A355E9743Q41546012-14188C50-CF32-41C5-A0FF-7210D2C1164AQ43083912-5B4C0287-A2D7-4960-A639-42CE3F1BAB9BQ44630306-CBB66908-9E7B-4FCA-9B6F-B796EA08C06EQ47663969-B2EBEB89-4BA4-41BF-A17B-91026936BAE2Q48324759-EB043985-C33C-4DA5-B927-3D81B55BAF4AQ51032370-57D28C9A-D9FD-479F-A7EF-17C431A9F3E6Q52568869-C6E2EBE9-948C-4041-B571-F5863C21A8B2Q53005041-D3B35CF5-4234-4A61-8369-0E1D86E2D02EQ53067238-96A0BCD5-AC72-475D-B174-BF8B8EB4892FQ55690940-AA5B9AF9-D608-4CFD-866E-DB4C3E915403
P2860
Novel agonists and antagonists for human protease activated receptor 2.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Novel agonists and antagonists for human protease activated receptor 2.
@ast
Novel agonists and antagonists for human protease activated receptor 2.
@en
Novel agonists and antagonists for human protease activated receptor 2.
@nl
type
label
Novel agonists and antagonists for human protease activated receptor 2.
@ast
Novel agonists and antagonists for human protease activated receptor 2.
@en
Novel agonists and antagonists for human protease activated receptor 2.
@nl
prefLabel
Novel agonists and antagonists for human protease activated receptor 2.
@ast
Novel agonists and antagonists for human protease activated receptor 2.
@en
Novel agonists and antagonists for human protease activated receptor 2.
@nl
P2093
P356
P1476
Novel agonists and antagonists for human protease activated receptor 2.
@en
P2093
Adam Cotterell
David P Fairlie
Giang T Le
Grant D Barry
Jacky Y Suen
Robert C Reid
P304
P356
10.1021/JM100984Y
P407
P577
2010-10-01T00:00:00Z